Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results
24 Julho 2023 - 9:00AM
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that it will report second
quarter ended June 30, 2023 financial results after the close
on Monday, August 7, 2023. Following distribution of the
earnings release via wire services, the Ocular Therapeutix
management team will host a live conference call and webcast
at 4:30 p.m. Eastern Time to review the Company’s financial
results and provide a general business update.
Listeners can register for the webcast via this
link. Those who plan on participating are advised to join 15
minutes prior to the start time. Analysts wishing to participate in
the question and answer session should use this link. A replay of
the webcast will be available via the Company’s investor website
approximately two hours after the call’s conclusion for 90
days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye using its proprietary bioresorbable
hydrogel-based formulation technology. Ocular Therapeutix’s first
commercial drug product, DEXTENZA®, is an FDA-approved
corticosteroid for the treatment of ocular inflammation and pain
following ophthalmic surgery and ocular itching associated with
allergic conjunctivitis. Ocular Therapeutix’s earlier stage
development assets include: OTX-TKI (axitinib intravitreal
implant), currently in Phase 1 clinical trials for the treatment of
wet AMD and diabetic retinopathy; OTX-TIC (travoprost intracameral
implant), currently in a Phase 2 clinical trial for the treatment
of primary open-angle glaucoma or ocular hypertension; and OTX-CSI
(cyclosporine intracanalicular insert) for the chronic treatment of
dry eye disease and OTX-DED (dexamethasone intracanalicular insert)
for the short-term treatment of the signs and symptoms of dry eye
disease, both of which have completed Phase 2 clinical trials.
InvestorsOcular TherapeutixDonald
NotmanChief Financial Officerdnotman@ocutx.comorICR WestwickeChris
Brinzey, 339-970-2843Managing
Directorchris.brinzey@westwicke.com
MediaICR WestwickeBen Shannon,
443-213-0495ben.shannon@westwicke.com
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024